Report Content
Chapter 1 Methodology & Scope
1.1 Methodology
1.2 Market scope and definitions
1.3 Base estimates and working
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data sources
1.7.1 Primary
1.7.2 Secondary
1.7.2.1 Paid sources
1.7.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Oncology industry 360° synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Cancer diagnostic & treatment trends
2.1.3 Cancer type trends
2.1.4 End-use trends
2.1.5 Regional trends
Chapter 3 Oncology Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2018 - 2032
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Rising incidence of cancer globally
3.3.1.2 Several initiatives undertaken by government and other organizations to spread disease awareness
3.3.1.3 Growing number of diagnostic laboratories in developing countries
3.3.1.4 Technological advancements in developed countries
3.3.2 Industry pitfalls & challenges
3.3.2.1 High capital investment coupled with high cost associated with diagnostic imaging system
3.3.2.2 High risk of side effects associated with cancer treatment and risks associated with CT scanners
3.3.2.3 Dearth of well-skilled and trained oncologists and radiologists
3.4 Growth potential analysis
3.4.1 By cancer diagnostics & treatment
3.4.2 By cancer type
3.4.3 By end-use
3.5 COVID- 19 impact analysis
3.6 Oncology clinical trial volume analysis, 2021
3.6.1 Oncology clincial trial volume, by region, 2017 - 2021
3.6.2 Oncology clinical trial volume, by cancer type, 2017 - 2021
3.6.3 Oncology clinical trial volume, by phase of development, 2017 - 2021
3.7 Pipeline analysis
3.8 Porter’s analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2021
4.1 Introduction
4.2 Company matrix analysis
4.3 Top oncology drugs, by company, 2021
4.4 Competitive analysis of major market players
4.4.1 F. Hoffmann-La Roche
4.4.2 Janssen Diagnostics, LCC
4.4.3 Pfizer, Inc
4.4.4 GE Healthcare
4.5 Oncology drugs company market share analysis, 2021
4.6 Strategic dashboard
Chapter 5 Oncology Market, By Cancer Diagnostics & Treatment
5.1 Key cancer diagnostics & treatment trends
5.2 Cancer diagnostics
5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.2.2 Tumor biomarkers tests
5.2.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.2.3 Imaging
5.2.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.2.4 Biopsy
5.2.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.2.5 Liquid biopsy
5.2.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.2.6 Immunohistochemistry
5.2.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.2.7 In situ hybridization
5.2.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3 Cancer treatment
5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3.2 Immunohistochemistry
5.3.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3.3 Targeted therapy
5.3.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3.4 Immunotherapy
5.3.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3.5 Hormonal therapy
5.3.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3.6 Others
5.3.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 6 Oncology Market, By Cancer Type
6.1 Key cancer type trends
6.2 Lung cancer
6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3 Prostate cancer
6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.4 Colon & rectal cancer
6.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.5 Gastric cancer
6.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.6 Esophageal cancer
6.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.7 Liver cancer
6.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.8 Breast cancer
6.8.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.9 Others
6.9.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 7 Oncology Market, By End-use
7.1 Key end-use trends
7.2 Hospitals
7.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.3 Diagnostic laboratories
7.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.4 Diagnostic imaging centers
7.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.5 Academia
7.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.6 Specialty clinics
7.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.7 Others
7.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 8 Oncology Market, By Region
8.1 Key regional trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Poland
8.3.7 Switzerland
8.3.8 Netherlands
8.4 Asia Pacific
8.4.1 China
8.4.2 India
8.4.3 Japan
8.4.4 Australia
8.4.5 South Korea
8.4.6 Indonesia
8.4.7 Thailand
8.4.8 Vietnam
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Columbia
8.6 MEA
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Israel
Chapter 9 Company Profiles
9.1 Abbott
9.2 Bayer AG
9.3 Biocartis
9.4 BioMerieux SA
9.5 Bio-Rad Laboratories
9.6 GE Healthcare
9.7 Astellas Pharma, Inc.
9.8 AstraZeneca
9.9 Janssen Diagnostic LLC (Johnson & Johnson)
9.10 F. Hoffmann-La Roche Ltd
9.11 Sysmex Corporation
9.12 Thermo Fischer Scientific
9.13 Siemens Healthineers
9.14 Kite Pharma (Gilead Sciences Inc)
9.15 Amgen
9.16 AstraZeneca
9.17 Merck & Co.
9.18 Abbive Inc.
9.19 Pfizer
